Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 3;14(6):994-1017.
doi: 10.1158/2159-8290.CD-24-0027.

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang  1 , Lingyan Jiang #  1 , Benjamin J Maldonato #  1 , Yingyun Wang  1 , Matthew Holderfield  1 , Ida Aronchik  1 , Ian P Winters  1   2 , Zeena Salman  1 , Cristina Blaj  1 , Marie Menard  1 , Jens Brodbeck  1 , Zhe Chen  1 , Xing Wei  1 , Michael J Rosen  2 , Yevgeniy Gindin  1 , Bianca J Lee  1 , James W Evans  1 , Stephanie Chang  1 , Zhican Wang  1 , Kyle J Seamon  1 , Dylan Parsons  1 , James Cregg  1 , Abby Marquez  1 , Aidan C A Tomlinson  1 , Jason K Yano  1 , John E Knox  1 , Elsa Quintana  1 , Andrew J Aguirre  3   4   5   6 , Kathryn C Arbour  7 , Abby Reed  8 , W Clay Gustafson  1 , Adrian L Gill  1 , Elena S Koltun  1 , David Wildes  1 , Jacqueline A M Smith  1 , Zhengping Wang  1 , Mallika Singh  1
Affiliations

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang et al. Cancer Discov. .

Abstract

RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC-6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models. Translational PK/efficacy and PK/PD modeling predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively, in patients with RAS-driven tumors. Consistent with this, we describe here objective responses in two patients (at 300 mg daily) with advanced KRASG12X lung and pancreatic adenocarcinoma, respectively, demonstrating the initial activity of RMC-6236 in an ongoing phase I/Ib clinical trial (NCT05379985).

Significance: The discovery of RMC-6236 enables the first-ever therapeutic evaluation of targeted and concurrent inhibition of canonical mutant and wild-type RAS-GTP in RAS-driven cancers. We demonstrate that broad-spectrum RAS-GTP inhibition is tolerable at exposures that induce profound tumor regressions in preclinical models of, and in patients with, such tumors. This article is featured in Selected Articles from This Issue, p. 897.

PubMed Disclaimer

Figures

Figure 1. RMC-6236 is a potent noncovalent inhibitor of the GTP-bound state of multiple RAS variants in vitro. A, Chemical structure of RMC-6236. B, Biochemical potency of RMC-6236 for wild-type KRAS, NRAS, HRAS, and several oncogenic RAS variants. EC50 values shown for inhibition of RAS-RAF binding using recombinant proteins in vitro. Error bars indicate ± 95% CI. C, Immunoblot protein Western analyses of KRAS pathway targets in HPAC (KRASG12D/WT, PDAC) and Capan-2 (KRASG12V/WT, PDAC) cancer cells treated with RMC-6236 at the indicated concentrations and time points. D, RMC-6236 potency measured in the PRISM panel of cancer cell lines. Left, AUC difference between cell lines with and without a given gene mutation (x-axis) and the significance of the difference (y-axis). Points represent mutated genes. A negative AUC indicates increased sensitivity to RMC-6236 and positive AUC indicates resistance. Horizontal dashed line represents the P-value cutoff of 5 × 10−8. Vertical lines represent the absolute effect cutoff of 0.1. Right: AUC for KRAS mutant [glycine 12 depicted as KRASG12X (115 lines); all other KRAS mutations labeled KRASOther (42 lines)], NRAS mutant [glutamine 61 depicted as NRASQ61X (34 lines); all other NRAS mutations labeled as NRASOther (20 lines)], HRAS mutant, NF1 mutant, EGFR mutant, PTPN11 mutant, and BRAFV600E mutant cell lines are shown. Comparison of indicated groups was done by the Wilcoxon rank-sum test with continuity correction. (**, P < 0.01; ***, P < 0.001).
Figure 1.
RMC-6236 is a potent noncovalent inhibitor of the GTP-bound state of multiple RAS variants in vitro. A, Chemical structure of RMC-6236. B, Biochemical potency of RMC-6236 for wild-type KRAS, NRAS, HRAS, and several oncogenic RAS variants. EC50 values shown for inhibition of RAS-RAF binding using recombinant proteins in vitro. Error bars indicate ± 95% CI. C, Immunoblot protein Western analyses of KRAS pathway targets in HPAC (KRASG12D/WT, PDAC) and Capan-2 (KRASG12V/WT, PDAC) cancer cells treated with RMC-6236 at the indicated concentrations and time points. D, RMC-6236 potency measured in the PRISM panel of cancer cell lines. Left, AUC difference between cell lines with and without a given gene mutation (x-axis) and the significance of the difference (y-axis). Points represent mutated genes. A negative AUC indicates increased sensitivity to RMC-6236 and positive AUC indicates resistance. Horizontal dashed line represents the P-value cutoff of 5 × 10−8. Vertical lines represent the absolute effect cutoff of 0.1. Right: AUC for KRAS mutant [glycine 12 depicted as KRASG12X (115 lines); all other KRAS mutations labeled KRASOther (42 lines)], NRAS mutant [glutamine 61 depicted as NRASQ61X (34 lines); all other NRAS mutations labeled as NRASOther (20 lines)], HRAS mutant, NF1 mutant, EGFR mutant, PTPN11 mutant, and BRAFV600E mutant cell lines are shown. Comparison of indicated groups was done by the Wilcoxon rank-sum test with continuity correction. (**, P < 0.01; ***, P < 0.001).
Figure 2. RMC-6236 inhibits RAS signaling and tumor growth and drives tumor regressions in vivo. A, Blood and tumor PK profiles of RMC-6236 in Capan-2 (KRASG12V/WT, PDAC) xenograft tumor-bearing BALB/c nude mice. Tumor-bearing mice were treated with a single dose of vehicle or RMC-6236 at 3, 10, or 25 mg/kg. Blood and tumors were harvested at indicated time points (n = 3/time point/dose). PK profiles are shown as RMC-6236 concentration in tumors (green lines) and blood (red lines) over time. Shades of green or red represent PK profiles at three tested doses. The dashed lines represent EC50 and EC90 potency of RMC-6236 in inhibiting DUSP6 mRNA expression in Capan-2 tumors derived from the PK/PD relationship curve in Fig. 5A. Values are plotted as mean ± SEM. B, PD of RMC-6236 in Capan-2 (KRASG12V/WT, PDAC) xenograft tumors, shown as the relative change in DUSP6 mRNA expression. Tumor-bearing mice were treated with a single dose (solid lines) of vehicle, RMC-6236 at 3, 10, or 25 mg/kg, or 7 consecutive daily doses of RMC-6236 at 25 mg/kg (dashed lines). Shades of green represent three tested doses. Solid lines represent a single dose while the dashed line represents repeat dosing. Values are plotted as mean ± SEM. C, Histopathology analysis of Capan-2 xenograft tumors treated with a single dose of vehicle control, or RMC-6236 at 3, 10, or 25 mg/kg or 7 consecutive daily doses of RMC-6236 at 25 mg/kg and collected at indicated time points (n = 2–3/time point/dose). pERK staining in tumor areas was quantified and compared with vehicle using one-way ANOVA followed by Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Representative images are shown at 200× magnification from samples closest to the mean of the group. Scale bar, 50 μm. D–G, Dose-dependent antitumor activity of RMC-6236 in subcutaneous xenograft models of (D) Capan-2 (KRASG12V/WT, PDAC; n = 8 per group), po qd, per os quaqua (once a day) (E) NCI-H441 (KRASG12V/WT, NSCLC; n = 10 per group), (F) HPAC (KRASG12D/WT, PDAC; n = 10 per group), and (G) NCI-H358 (KRASG12C/WT, NSCLC; n = 8–10 per group). Tumor-bearing mice were treated with vehicle or RMC-6236 at indicated doses for 27–28 days, and mean tumor volumes of each group were plotted over the course of treatment. Vehicle control and RMC-6236 groups were compared by two-way repeated-measures ANOVA on the last measurement day of the vehicle group (***, P < 0.001). The dotted line indicates the initial average tumor volume. Error bars, SEM. # indicates 1 animal terminated upon reaching a tumor burden endpoint.
Figure 2.
RMC-6236 inhibits RAS signaling and tumor growth and drives tumor regressions in vivo.A, Blood and tumor PK profiles of RMC-6236 in Capan-2 (KRASG12V/WT, PDAC) xenograft tumor-bearing BALB/c nude mice. Tumor-bearing mice were treated with a single dose of vehicle or RMC-6236 at 3, 10, or 25 mg/kg. Blood and tumors were harvested at indicated time points (n = 3/time point/dose). PK profiles are shown as RMC-6236 concentration in tumors (green lines) and blood (red lines) over time. Shades of green or red represent PK profiles at three tested doses. The dashed lines represent EC50 and EC90 potency of RMC-6236 in inhibiting DUSP6 mRNA expression in Capan-2 tumors derived from the PK/PD relationship curve in Fig. 5A. Values are plotted as mean ± SEM. B, PD of RMC-6236 in Capan-2 (KRASG12V/WT, PDAC) xenograft tumors, shown as the relative change in DUSP6 mRNA expression. Tumor-bearing mice were treated with a single dose (solid lines) of vehicle, RMC-6236 at 3, 10, or 25 mg/kg, or 7 consecutive daily doses of RMC-6236 at 25 mg/kg (dashed lines). Shades of green represent three tested doses. Solid lines represent a single dose while the dashed line represents repeat dosing. Values are plotted as mean ± SEM. C, Histopathology analysis of Capan-2 xenograft tumors treated with a single dose of vehicle control, or RMC-6236 at 3, 10, or 25 mg/kg or 7 consecutive daily doses of RMC-6236 at 25 mg/kg and collected at indicated time points (n = 2–3/time point/dose). pERK staining in tumor areas was quantified and compared with vehicle using one-way ANOVA followed by Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Representative images are shown at 200× magnification from samples closest to the mean of the group. Scale bar, 50 μm. D–G, Dose-dependent antitumor activity of RMC-6236 in subcutaneous xenograft models of (D) Capan-2 (KRASG12V/WT, PDAC; n = 8 per group), po qd, per os quaqua (once a day) (E) NCI-H441 (KRASG12V/WT, NSCLC; n = 10 per group), (F) HPAC (KRASG12D/WT, PDAC; n = 10 per group), and (G) NCI-H358 (KRASG12C/WT, NSCLC; n = 8–10 per group). Tumor-bearing mice were treated with vehicle or RMC-6236 at indicated doses for 27–28 days, and mean tumor volumes of each group were plotted over the course of treatment. Vehicle control and RMC-6236 groups were compared by two-way repeated-measures ANOVA on the last measurement day of the vehicle group (***, P < 0.001). The dotted line indicates the initial average tumor volume. Error bars, SEM. # indicates 1 animal terminated upon reaching a tumor burden endpoint.
Figure 3. Broad-spectrum antitumor activity of RMC-6236 in preclinical models of RAS-addicted cancers. A–C, Tumor response waterfall plots of KRASG12X NSCLC (A), PDAC (B), and colorectal cancer (C) xenograft models upon RMC-6236 daily treatment at 25 mg/kg. 29 NSCLC, 22 PDAC, and 23 colorectal cancer xenograft models were included (n = 1–10 per model). Average % mean tumor volume change ± SEM from baseline at response calling date are shown. mRECIST criteria were used to call tumor response as indicated on the right-hand side of each waterfall plot. Oncoplots illustrating gene alterations and expression levels in critical genes linked to the clinicopathologic characteristics of the indicated models are shown below each waterfall. Color coding represents dark green for mutations and light green for the absence of mutations. The ◈ symbol denotes that mRNA expression of corresponding genes not expressed, defined as having a gene-expression value of ≤0.5 CPM. The top row specifically highlights the mutation codon at KRASG12. D–F, Kaplan–Meier analyses of time to tumor doubling on treatment in individual tumor-bearing animals from KRASG12X NSCLC (D), PDAC (E), and colorectal cancer (F) xenograft models upon daily treatment of vehicle control or RMC-6236 at 25 mg/kg for up to 90 days. 29 NSCLC models (n = 135 animals each in control and RMC-6236 treatment groups), 22 PDAC models (n = 95 animals in control, n = 83 in RMC-6236 treatment group), and 23 colorectal cancer models (n = 95 animals in control, n = 93 in RMC-6236 treatment group) were included. Time to event was determined by the time on treatment until tumor volume doubling from baseline on survival plots by Kaplan–Meier analysis. Log-rank test was used to compare vehicle control with treatment groups, Cox proportional hazards models were used to estimate hazard ratios: KRASG12X NSCLC (HR 0.035, 95% interval 0.020–0.061, P < 2 × 10−16), KRASG12X PDAC (HR 0.008, 95% interval 0.002–0.026, P < 2 × 10−16) and KRASG12X colorectal cancer (HR 0.072, 95% interval 0.043–0.120, P < 2 × 10−16). G, Tumor response waterfall plot and Kaplan–Meier analysis of KRASG12X GAC and OVCA xenograft models upon daily treatment of vehicle control or RMC-6236 at 25 mg/kg for up to 90 days. Four models of GAC and 4 models of OVCA tumors were included. Average % mean tumor volume change ± SEM from baseline at the response calling date were plotted. mRECIST criteria were used to call tumor response as indicated on right-hand side of the waterfall plot. Time to event was determined above. H, Bar plots of mean tumor volume % change ± SEM from baseline for xenograft models of NSCLC with KRASG12X and KRASOther mutations. Data for both vehicle control and RMC-6236 treatment groups of 35 KRASMUT NSCLC models (29 KRASG12X and 6 KRASOther models) are shown with each model represented by one symbol. The genotype of each model was represented by color and shapes: KRASG12X (green dot), KRASOther (purple; KRASG13X, square; KRASQ61H, triangle; KRASK117N, star). Mean tumor volume % change from baseline of the vehicle control groups and RMC-6236 treatment groups for KRASG12X models are 708.1% and −13.7% respectively; for KRASOther models are 1,070% and 257.5%, respectively. Vehicle control and RMC-6236 treatment groups were compared by paired t test, with P < 0.001 (***) for KRASG12X models and P < 0.01 (**) for KRASOther models. The dotted line represents mean baseline tumor volume.
Figure 3.
Broad-spectrum antitumor activity of RMC-6236 in preclinical models of RAS-addicted cancers. A–C, Tumor response waterfall plots of KRASG12X NSCLC (A), PDAC (B), and colorectal cancer (C) xenograft models upon RMC-6236 daily treatment at 25 mg/kg. 29 NSCLC, 22 PDAC, and 23 colorectal cancer xenograft models were included (n = 1–10 per model). Average % mean tumor volume change ± SEM from baseline at response calling date are shown. mRECIST criteria were used to call tumor response as indicated on the right-hand side of each waterfall plot. Oncoplots illustrating gene alterations and expression levels in critical genes linked to the clinicopathologic characteristics of the indicated models are shown below each waterfall. Color coding represents dark green for mutations and light green for the absence of mutations. The ◈ symbol denotes that mRNA expression of corresponding genes not expressed, defined as having a gene-expression value of ≤0.5 CPM. The top row specifically highlights the mutation codon at KRASG12. D–F, Kaplan–Meier analyses of time to tumor doubling on treatment in individual tumor-bearing animals from KRASG12X NSCLC (D), PDAC (E), and colorectal cancer (F) xenograft models upon daily treatment of vehicle control or RMC-6236 at 25 mg/kg for up to 90 days. 29 NSCLC models (n = 135 animals each in control and RMC-6236 treatment groups), 22 PDAC models (n = 95 animals in control, n = 83 in RMC-6236 treatment group), and 23 colorectal cancer models (n = 95 animals in control, n = 93 in RMC-6236 treatment group) were included. Time to event was determined by the time on treatment until tumor volume doubling from baseline on survival plots by Kaplan–Meier analysis. Log-rank test was used to compare vehicle control with treatment groups, Cox proportional hazards models were used to estimate hazard ratios: KRASG12X NSCLC (HR 0.035, 95% interval 0.020–0.061, P < 2 × 10−16), KRASG12X PDAC (HR 0.008, 95% interval 0.002–0.026, P < 2 × 10−16) and KRASG12X colorectal cancer (HR 0.072, 95% interval 0.043–0.120, P < 2 × 10−16). G, Tumor response waterfall plot and Kaplan–Meier analysis of KRASG12X GAC and OVCA xenograft models upon daily treatment of vehicle control or RMC-6236 at 25 mg/kg for up to 90 days. Four models of GAC and 4 models of OVCA tumors were included. Average % mean tumor volume change ± SEM from baseline at the response calling date were plotted. mRECIST criteria were used to call tumor response as indicated on right-hand side of the waterfall plot. Time to event was determined above. H, Bar plots of mean tumor volume % change ± SEM from baseline for xenograft models of NSCLC with KRASG12X and KRASOther mutations. Data for both vehicle control and RMC-6236 treatment groups of 35 KRASMUT NSCLC models (29 KRASG12X and 6 KRASOther models) are shown with each model represented by one symbol. The genotype of each model was represented by color and shapes: KRASG12X (green dot), KRASOther (purple; KRASG13X, square; KRASQ61H, triangle; KRASK117N, star). Mean tumor volume % change from baseline of the vehicle control groups and RMC-6236 treatment groups for KRASG12X models are 708.1% and −13.7% respectively; for KRASOther models are 1,070% and 257.5%, respectively. Vehicle control and RMC-6236 treatment groups were compared by paired t test, with P < 0.001 (***) for KRASG12X models and P < 0.01 (**) for KRASOther models. The dotted line represents mean baseline tumor volume.
Figure 4. Translating RMC-6236 activity in NSCLC. A, Efficacy of RMC-6236 on KrasG12C, KrasG12D, KrasG12V, KrasG12A, KrasG13D, or KrasQ61H-driven autochthonous lung tumors in immunocompetent mice. A pool of lentiviral cDNA vectors encoding each oncogenic Kras variant was delivered intratracheally to the lungs of each mouse, and 13 weeks after tumor growth, mice were treated with RMC-6236 at 20 mg/kg po qd for 3 weeks prior to analysis. 95% confidence intervals are shown. B, Efficacy of RMC-6236 and adagrasib in the LUN055 NSCLC PDX model with KRASG12C allele copy-number gain. Immunoblot Western analyses (left) of RAS and KRAS protein levels in NCI-H358 (KRASG12C/WT, NSCLC), LU99 (KRASG12C/WT, NSCLC), NCI-H2122 (KRASG12C/G12C, NSCLC), and LUN055 (KRASG12C/WT, NSCLC) xenograft tumors. Relative copy-number (middle) of KRASWT or KRASG12C in LUN055 xenograft tumors (n = 2) were determined by ddPCR and normalized to ACTB. LUN055 xenograft tumor-bearing mice were treated with vehicle or RMC-6236 at 25 mg/kg po qd or adagrasib at 100 mg/kg po qd for 24 to 28 days (n = 3 per group, right). Mean tumor volumes of each group were plotted over the course of treatment. Dotted line indicates the initial average tumor volume. Error bars, SEM. C, Efficacy of RMC-6236 in the intracranially implanted LU99-Luc (KRASG12C/WT, NSCLC) xenograft model (n = 8 per group). RMC-6236 was dosed at 25 mg/kg daily for 21 days. Images of bioluminescence in individual mice were shown. Bioluminescence of ROI in vehicle control and RMC-6236 groups were compared by two-way repeated-measures ANOVA at day 21 (**, P < 0.01). Results were shown as mean ± SEM. D, Antitumor activity of RMC-6236 and the combination with anti–PD-1 (clone RMP1-14, rat IgG2a) following repeated administration in BALB/c mice bearing the murine colon carcinoma eCT26 (KrasG12C/G12C) shown as individual tumor growth curves (n = 10 per group). Graphs indicate the number of complete regressions per injected mice. RMC-6236 and anti–PD-1 treatment started on day 17 after implantation. RMC-6236 treatment was stopped at day 31 after implantation and anti–PD-1 at day 35 after implantation. E, Antitumor activity of RMC-6236 following repeated administration in NSG mice bearing the murine colon carcinoma eCT26 (KrasG12C/G12C) shown as individual tumor growth curves (n = 10 per group). Graphs indicate the number of complete regressions per injected mice. RMC-6236 treatment started on day 16 after implantation. F, Immune cell composition (CD8+ and CD4+ T cells, Ly6C+ and Ly6G+ myeloid-derived suppressor cells and M2 macrophages) in murine colon carcinoma eCT26 syngeneic tumors (KrasG12C/G12C) represented as percentage of CD45+ cells and expression of cell-surface markers on viable, CD45− large cells (assessed as tumor cells) 24 hours post 4 days of treatment with vehicle or RMC-6236 at 25 mg/kg po qd n = 3 biological replicates/group represented as mean; *, P < 0.05; **, P < 0.01; ns, nonsignificant by two-sided Student t test.
Figure 4.
Translating RMC-6236 activity in NSCLC. A, Efficacy of RMC-6236 on KrasG12C, KrasG12D, KrasG12V, KrasG12A, KrasG13D, or KrasQ61H-driven autochthonous lung tumors in immunocompetent mice. A pool of lentiviral cDNA vectors encoding each oncogenic Kras variant was delivered intratracheally to the lungs of each mouse, and 13 weeks after tumor growth, mice were treated with RMC-6236 at 20 mg/kg po qd for 3 weeks prior to analysis. 95% confidence intervals are shown. B, Efficacy of RMC-6236 and adagrasib in the LUN055 NSCLC PDX model with KRASG12C allele copy-number gain. Immunoblot Western analyses (left) of RAS and KRAS protein levels in NCI-H358 (KRASG12C/WT, NSCLC), LU99 (KRASG12C/WT, NSCLC), NCI-H2122 (KRASG12C/G12C, NSCLC), and LUN055 (KRASG12C/WT, NSCLC) xenograft tumors. Relative copy-number (middle) of KRASWT or KRASG12C in LUN055 xenograft tumors (n = 2) were determined by ddPCR and normalized to ACTB. LUN055 xenograft tumor-bearing mice were treated with vehicle or RMC-6236 at 25 mg/kg po qd or adagrasib at 100 mg/kg po qd for 24 to 28 days (n = 3 per group, right). Mean tumor volumes of each group were plotted over the course of treatment. Dotted line indicates the initial average tumor volume. Error bars, SEM. C, Efficacy of RMC-6236 in the intracranially implanted LU99-Luc (KRASG12C/WT, NSCLC) xenograft model (n = 8 per group). RMC-6236 was dosed at 25 mg/kg daily for 21 days. Images of bioluminescence in individual mice were shown. Bioluminescence of ROI in vehicle control and RMC-6236 groups were compared by two-way repeated-measures ANOVA at day 21 (**, P < 0.01). Results were shown as mean ± SEM. D, Antitumor activity of RMC-6236 and the combination with anti–PD-1 (clone RMP1-14, rat IgG2a) following repeated administration in BALB/c mice bearing the murine colon carcinoma eCT26 (KrasG12C/G12C) shown as individual tumor growth curves (n = 10 per group). Graphs indicate the number of complete regressions per injected mice. RMC-6236 and anti–PD-1 treatment started on day 17 after implantation. RMC-6236 treatment was stopped at day 31 after implantation and anti–PD-1 at day 35 after implantation. E, Antitumor activity of RMC-6236 following repeated administration in NSG mice bearing the murine colon carcinoma eCT26 (KrasG12C/G12C) shown as individual tumor growth curves (n = 10 per group). Graphs indicate the number of complete regressions per injected mice. RMC-6236 treatment started on day 16 after implantation. F, Immune cell composition (CD8+ and CD4+ T cells, Ly6C+ and Ly6G+ myeloid-derived suppressor cells and M2 macrophages) in murine colon carcinoma eCT26 syngeneic tumors (KrasG12C/G12C) represented as percentage of CD45+ cells and expression of cell-surface markers on viable, CD45− large cells (assessed as tumor cells) 24 hours post 4 days of treatment with vehicle or RMC-6236 at 25 mg/kg po qd n = 3 biological replicates/group represented as mean; *, P < 0.05; **, P < 0.01; ns, nonsignificant by two-sided Student t test.
Figure 5. Effects of RMC-6236 mediated pharmacologic modulation of RAS pathway signaling in tumor-bearing mice. A, PK/PD relationship between RMC-6236 concentration and inhibition of DUSP6 expression in Capan-2 (EC50 = 90 nmol/L and EC90 = 809 nmol/L), NCI-H441 (EC50 = 117 nmol/L and EC90 = 1,121 nmol/L), and HPAC (EC50 = 135 nmol/L and EC90 = 925 nmol/L) xenograft tumors. Subcutaneous xenograft tumors were treated with vehicle or RMC-6236 ranging from 0.3 to 100 mg/kg (Capan-2 and H441) or to 50 mg/kg (HPAC). B, PK/PD relationship between RMC-6236 concentration and inhibition of Dusp6 expression in ear skin (EC50 = 1,164 nmol/L and EC90 = 10,279 nmol/L) isolated from tumor-bearing BALB/c nude mice treated with vehicle or RMC-6236 ranging from 3 mg/kg to 100 mg/kg. A and B, Tumors and ear skin from tumor-bearing BALB/c nude mice were harvested at indicated time points (n = 3/timepoint/dose). A 3-parameter sigmoidal exposure–response model was fitted to the data to derive EC50 and EC90 values. Time points are represented by colors and doses are represented by symbol shapes. C–G, Histopathology of tumors and ear skin from the Capan-2 xenograft model collected at indicated time points post a single dose of vehicle control, RMC-6236 at 25 mg/kg or 7 consecutive daily doses of RMC-6236 at 25 mg/kg (n = 3–6/time point/dose). Staining of indicated markers in the tumor area or ear skin was quantified and compared with vehicle using one-way ANOVA followed by the Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Representative images are shown at 200× magnification from samples closest to the mean of the respective groups. Scale bar, 50 μm.
Figure 5.
Effects of RMC-6236 mediated pharmacologic modulation of RAS pathway signaling in tumor-bearing mice. A, PK/PD relationship between RMC-6236 concentration and inhibition of DUSP6 expression in Capan-2 (EC50 = 90 nmol/L and EC90 = 809 nmol/L), NCI-H441 (EC50 = 117 nmol/L and EC90 = 1,121 nmol/L), and HPAC (EC50 = 135 nmol/L and EC90 = 925 nmol/L) xenograft tumors. Subcutaneous xenograft tumors were treated with vehicle or RMC-6236 ranging from 0.3 to 100 mg/kg (Capan-2 and H441) or to 50 mg/kg (HPAC). B, PK/PD relationship between RMC-6236 concentration and inhibition of Dusp6 expression in ear skin (EC50 = 1,164 nmol/L and EC90 = 10,279 nmol/L) isolated from tumor-bearing BALB/c nude mice treated with vehicle or RMC-6236 ranging from 3 mg/kg to 100 mg/kg. A and B, Tumors and ear skin from tumor-bearing BALB/c nude mice were harvested at indicated time points (n = 3/timepoint/dose). A 3-parameter sigmoidal exposure–response model was fitted to the data to derive EC50 and EC90 values. Time points are represented by colors and doses are represented by symbol shapes. C–G, Histopathology of tumors and ear skin from the Capan-2 xenograft model collected at indicated time points post a single dose of vehicle control, RMC-6236 at 25 mg/kg or 7 consecutive daily doses of RMC-6236 at 25 mg/kg (n = 3–6/time point/dose). Staining of indicated markers in the tumor area or ear skin was quantified and compared with vehicle using one-way ANOVA followed by the Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Representative images are shown at 200× magnification from samples closest to the mean of the respective groups. Scale bar, 50 μm.
Figure 6. PK/PD/Efficacy modeling to predict clinically active dose range. A, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the NCI-H441 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. B, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the Capan-2 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. C, Comparison of observed vs. simulated PK and PD data at multiple dose levels of RMC-6236 in mice bearing NCI-H441 xenograft tumors. Single-dose data from all dose levels are presented from 0 to 24 hours, whereas repeat-dose data from 25 and 40 mg/kg repeat daily dosing is presented from 216 to 240 hours. Simulated blood and tumor PK data are indicated by the solid and dashed green and blue lines, respectively. Simulated PD data are indicated by the solid purple lines. Observed data are indicated by dots (blood PK and PD) or squares (tumor PK). The dotted line indicates the 10% expression level of DUSP6 mRNA as normalized to the vehicle control group. D, Predicted profiles of human whole blood and tumor PK as well as tumor PD at clinical dose levels at steady state. Blood PK and tumor PK are indicated by the solid and dashed green lines whereas tumor PD is indicated by the solid purple lines. Repeat dose data are presented from 336 to 360 hours after two weeks of simulated daily dosing. The dotted line indicates a 10% expression level of DUSP6 mRNA as normalized to the vehicle control group.
Figure 6.
PK/PD/Efficacy modeling to predict clinically active dose range. A, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the NCI-H441 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. B, Comparison of observed and predicted tumor growth data at multiple dose levels of RMC-6236 in the Capan-2 xenograft tumor model. Tumor growth was predicted using the Simeoni tumor growth model. The dotted line indicates the initial average tumor volume. C, Comparison of observed vs. simulated PK and PD data at multiple dose levels of RMC-6236 in mice bearing NCI-H441 xenograft tumors. Single-dose data from all dose levels are presented from 0 to 24 hours, whereas repeat-dose data from 25 and 40 mg/kg repeat daily dosing is presented from 216 to 240 hours. Simulated blood and tumor PK data are indicated by the solid and dashed green and blue lines, respectively. Simulated PD data are indicated by the solid purple lines. Observed data are indicated by dots (blood PK and PD) or squares (tumor PK). The dotted line indicates the 10% expression level of DUSP6 mRNA as normalized to the vehicle control group. D, Predicted profiles of human whole blood and tumor PK as well as tumor PD at clinical dose levels at steady state. Blood PK and tumor PK are indicated by the solid and dashed green lines whereas tumor PD is indicated by the solid purple lines. Repeat dose data are presented from 336 to 360 hours after two weeks of simulated daily dosing. The dotted line indicates a 10% expression level of DUSP6 mRNA as normalized to the vehicle control group.
Figure 7. Activity of RMC-6236 in pancreatic and lung cancer patients. A, Pretreatment and 12-week (post cycle 4) scans of a heavily pretreated patient with a KRASG12D mutation-positive PDAC indicating a complete response of both target and nontarget lesions. Patient continued on study treatment in cycle 6. Axial views of computed tomography (CT) abdomen images prior to RMC-6236 treatment (top) and after four cycles of RMC-6236 treatment (bottom). B, Pretreatment and 6-week (post cycle 2) scans of a patient with a KRASG12V mutation-positive NSCLC indicating a complete response of target lesions (no nontarget lesions present at baseline), atelectatic changes in the right lung are also largely resolved by 6 weeks. Complete response was confirmed at cycle 4, and the patient continued on study treatment with a complete response in cycle 10. Axial views of computed tomography (CT) chest images prior to RMC-6236 treatment (top) and after two cycles of RMC-6236 treatment (bottom).
Figure 7.
Activity of RMC-6236 in pancreatic and lung cancer patients. A, Pretreatment and 12-week (post cycle 4) scans of a heavily pretreated patient with a KRASG12D mutation-positive PDAC indicating a complete response of both target and nontarget lesions. Patient continued on study treatment in cycle 6. Axial views of computed tomography (CT) abdomen images prior to RMC-6236 treatment (top) and after four cycles of RMC-6236 treatment (bottom). B, Pretreatment and 6-week (post cycle 2) scans of a patient with a KRASG12V mutation-positive NSCLC indicating a complete response of target lesions (no nontarget lesions present at baseline), atelectatic changes in the right lung are also largely resolved by 6 weeks. Complete response was confirmed at cycle 4, and the patient continued on study treatment with a complete response in cycle 10. Axial views of computed tomography (CT) chest images prior to RMC-6236 treatment (top) and after two cycles of RMC-6236 treatment (bottom).
See this image and copyright information in PMC

Similar articles

  • Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
    Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M. Holderfield M, et al. Nature. 2024 May;629(8013):919-926. doi: 10.1038/s41586-024-07205-6. Epub 2024 Apr 8. Nature. 2024. PMID: 38589574 Free PMC article.
  • Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
    Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, Lee B, Orlen M, Tian S, Stalnecker CA, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Muonio K, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs WP, Hibshman PS, Amparo AM, Hennessey C, Rees MG, Ronan MM, Roth JA, Brodbeck J, Tomassoni L, Bakir B, Socci ND, Herring LE, Barker NK, Wang J, Cleary JM, Wolpin BM, Chabot JA, Kluger MD, Manji GA, Tsai KY, Sekulic M, Lagana SM, Califano A, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Lowe SW, Badgley MA, Aguirre AJ, Vonderheide RH, Stanger BZ, Baslan T, Der CJ, Singh M, Olive KP. Wasko UN, et al. Nature. 2024 May;629(8013):927-936. doi: 10.1038/s41586-024-07379-z. Epub 2024 Apr 8. Nature. 2024. PMID: 38588697 Free PMC article.
  • RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, Wang Z, Kiss G, Koltun ES, Gill AL, Singh M, Goldsmith MA, Smith JAM, Bivona TG. Nichols RJ, et al. Nat Cell Biol. 2018 Sep;20(9):1064-1073. doi: 10.1038/s41556-018-0169-1. Epub 2018 Aug 13. Nat Cell Biol. 2018. PMID: 30104724 Free PMC article.
  • [Progress of targeted therapy related to K-ras mutation].
    Li ZW, Liu YQ. Li ZW, et al. Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):59-61. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 22455857 Review. Chinese. No abstract available.
  • Targeting Mutant KRAS for Anticancer Therapy.
    Chen F, Alphonse MP, Liu Y, Liu Q. Chen F, et al. Curr Top Med Chem. 2019;19(23):2098-2113. doi: 10.2174/1568026619666190902151307. Curr Top Med Chem. 2019. PMID: 31475898 Review.
See all similar articles

Cited by

References

    1. Foundation Medicine insights (version MI20220329) [cited 2023 Dec 03]. Available from: https://foundationmedicine.com/service/genomic-data-solutions.
    1. Cancer facts and figures 2023 [cited 2023 Dec 03]. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts....
    1. Cook JH, Melloni GEM, Gulhan DC, Park PJ, Haigis KM. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. Nat Commun 2021;12:1808. - PMC - PubMed
    1. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov 2020;19:533–52. - PMC - PubMed
    1. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, et al. . Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600–8. - PMC - PubMed

MeSH terms

Associated data